Elagolix and Buprenorphine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Elagolix
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Elagolix (Orilissa) can speed up the liver enzyme that breaks down your buprenorphine. That means your body may clear the buprenorphine faster, so there's less of it in your blood. The result can be weaker pain or withdrawal-symptom control, and you might start to feel opioid withdrawal (things like restlessness, sweating, chills, achiness, or nausea).
The good news: this is very manageable. Please don't stop or change either medicine on your own. Let your doctor or pharmacist know you're taking both, so they can adjust your buprenorphine dose if needed and keep a closer eye on how you're feeling.
Mechanism: Elagolix induces CYP3A4, increasing buprenorphine metabolism and lowering its plasma concentration/exposure. Neither agent is affected by prodrug considerations here; buprenorphine is the active moiety, so induction reduces its effect.
Effect: decreased buprenorphine exposure with risk of reduced efficacy and opioid withdrawal. Evidence: probable; onset unspecified; severity major.
Management:
- If starting elagolix, may need to titrate buprenorphine upward to stable effect; monitor for withdrawal.
- On elagolix discontinuation, consider buprenorphine dose reduction; monitor for respiratory depression.
- For long-acting subQ formulations, monitor adequacy; a formulation allowing finer dose adjustment may be preferred.
What happens
Reduced buprenorphine exposure and reduced efficacy of buprenorphine
Interaction Deep Dive
Concurrent administration of buprenorphine with a CYP3A4 inducer can lower plasma buprenorphine concentrations, potentially triggering opioid withdrawal symptoms. When a patient on buprenorphine requires a CYP3A4 inducer, one option is to raise the buprenorphine dose until stable drug effects are reached, along with monitoring for withdrawal. Conversely, if a CYP3A4 inducer is stopped in a patient being treated with buprenorphine, consider lowering the buprenorphine dose and watch for respiratory depression2. Should dose adjustment prove impossible once the CYP3A4 inducer is no longer present, switch the patient back to a buprenorphine formulation that allows finer dose titration. For patients transitioning from transmucosal buprenorphine given together with CYP3A4 inducers, confirm through monitoring that the plasma buprenorphine achieved with subQ buprenorphine is sufficient. When a patient already receiving subQ buprenorphine needs a CYP3A4 inducer, monitor for withdrawal. If the buprenorphine dose is inadequate while the concomitant drug is present and that drug cannot be reduced or discontinued, modify the buprenorphine dose. When the available doses cannot deliver the intended dose, use a buprenorphine formulation that permits more precise dose adjustments1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both medicines as prescribed unless your care team tells you otherwise. Because elagolix can lower your buprenorphine levels, your team may:
- Adjust your buprenorphine dose, individualized to keep your effect stable, and watch for withdrawal symptoms.
- Reduce the buprenorphine dose again if elagolix is later stopped, watching for over-sedation or slowed breathing.
- Consider a buprenorphine form that allows more precise dosing if needed.
What to do: Tell your pharmacist and prescriber you take both. Report any withdrawal signs (restlessness, sweating, chills, nausea, cramps) so they can fine-tune your dose and monitoring.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) The impact of a concurrently administered CYP3A4 inducer on buprenorphine exposure in individuals receiving subQ buprenorphine has not been investigated; nevertheless, these interactions have been demonstrated in studies employing transmucosal buprenorphine. The effects of buprenorphine may vary according to the route of administration 1.
Common questions
Can I take Elagolix and Buprenorphine together?
Elagolix can lower your buprenorphine levels and trigger opioid withdrawal or weaker effect. Don't change anything yourself; your care team can adjust the buprenorphine dose and monitor you closely. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Elagolix and Buprenorphine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Elagolix and Buprenorphine interaction managed?
Keep taking both medicines as prescribed unless your care team tells you otherwise. Because elagolix can lower your buprenorphine levels, your team may: Adjust your buprenorphine dose, individualized to keep your effect stable, and watch for withdrawal symptoms. Reduce the buprenorphine dose again if elagolix is later stopped, watching for over-sedation or slowed breathing. Consider a buprenorphin… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Elagolix or Buprenorphine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Buprenorphine
Keep reading about Elagolix
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist